Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc  

(Public, LON:GSK)   Watch this stock  
Find more results forGSK
1,721.50
0.00 (0.00%)
May 20 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range     -
52 week 1,314.00 - 1,737.26
Open     -
Vol / Avg. 0.00/3,158.00
Mkt cap 83,389.46M*
P/E 20.37
Div/yield 18.00/4.36*
EPS 0.85*
Shares 4,844.00M
Beta     -
Inst. own     -
*GBP
May 29, 2013
GlaxoSmithKline at Deutsche Bank dbAccess Health Care Conference Add to calendar
May 21, 2013
GlaxoSmithKline American Thoracic Society Conference Call - 6:00pm BST - Add to calendar
Apr 24, 2013
Q1 2013 GlaxoSmithKline PLC Earnings Conference Call
Apr 23, 2013
GlaxoSmithKline at Biotechnology Industry Organization (BIO) International Convention
Mar 11, 2013
GlaxoSmithKline at EBD BIO-Europe Spring
  

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 15.90% 17.95%
Operating margin 24.42% 27.97%
EBITD margin - 35.78%
Return on average assets 9.78% 11.49%
Return on average equity 61.70% 65.96%
Employees 98,681 -
Carbon Disclosure Rating - 90/100

Address

C8 Gsk House, 980 Great West Road
BRENTFORD, ENG TW8 9GS
United Kingdom - Map
+44-20-80475000 (Phone)
+44-20-80477807 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance
Discussion Group - Google Finance

Description

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK�s principal pharmaceutical products include medicines in therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and human immunodeficiency virus (HIV). The Company operates in three primary areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. On January 31, 2012, the Company completed the divestment of brands in the United States and Canada to Prestige Brands Holdings. In August 2012, it acquired Human Genome Sciences. On January 30, 2013, GSK acquired additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd.

Officers and directors

Andrew Philip Witty Chief Executive Officer, Executive Director
Age: 48
Simon Dingemans Chief Financial Officer, Executive Director
Age: 49
Moncef Slaoui Chairman - Research & Development, Executive Director
Age: 53
Deirdre P. Connelly President - North American Pharmaceuticals
Age: 52
Roger Connor President - Global Manufacturing & Supply
Marc Dunoyer Chairman - GSK Japan, Global Head - GSK Rare Diseases
Portrait
Shah Abbas Hussain President - Europe & EMAP
Age: 47
Patrick Vallance President - Pharmaceuticals R&D
Emma Walmsley President - Consumer Healthcare Worldwide
Christophe Weber President - Vaccines